Výsledky vyhledávání - "Paul Klekotka"

Akademický článek

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19

Autor: Dipak R. Patel, Lisa Macpherson, Martin Bohm, Himanshu Upadhyaya, Carmen Deveau, Ajay Nirula, Paul Klekotka, Mark Williams, Matthew M. Hufford

Publikováno v: Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2123-2134 (2024)

Abstract Introduction The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19. The EUA o

Externí odkaz: https://doaj.org/article/cf567da4bb5443c981f49175bf36b985

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers

Autor: Paul Klekotka, Louis Lavoie, Beth Mitchell, Ike Iheanacho, Russel Burge, Andrea Cohee, Joanne Puckett, Ajay Nirula

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

IntroductionSeveral current therapies for autoimmune diseases do not provide sustained remission. Therapies that focus on the restoration of homeostasis within the immune system (i.e., immune resolution) could overcome the limitations of current ther

Externí odkaz: https://doaj.org/article/4365c4d5d25c46fdb6aac5bf7520a9c3

Zobrazit plný text záznamu

Akademický článek

Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response

Autor: Marc-Kendy Paul, Manish Choudhary, Amy Heaps, Rinki Deo, Daniela Moisi, Kelley Gordon, John Mellors, Carlee Moser, Paul Klekotka, Alan Landay, Judith Currier, Joseph Eron, Kara Chew, Davey Smith, Scott Sieg, Urvi Parikh, Jonathan Li

Publikováno v: Pathogens and Immunity, Vol 9, Iss 2 (2024)

Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an antiviral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses and the development of monoclonal an

Externí odkaz: https://doaj.org/article/bdccb63bddb5442fabd3c42a04dba847

Zobrazit plný text záznamu

Akademický článek

Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment

Autor: Urvi Parikh, Amy Heaps, Daniela Moisi, Kelley Gordon, John Mellors, Manish Choudhary, Rinki Deo, Carlee Moser, Paul Klekotka, Alan Landay, Judith Currier, Joseph Eron, Kara Chew, Davey Smith, Jonathan Li, Scott Sieg, ACTIV-2/A5401 Study Team

Publikováno v: Pathogens and Immunity, Vol 9, Iss 2 (2024)

Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid measur

Externí odkaz: https://doaj.org/article/370dd23cdf414e01a8ece2d10d410282

Zobrazit plný text záznamu

Akademický článek

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)

In April 2021, Eli Lilly voluntarily asked the FDA to revoke the Emergency Use Authorization for the monoclonal antibody bamlanivimab due to reduced susceptibility in vitro to SARS-CoV-2 variants, not for safety. In this work, authors carry out a pla

Externí odkaz: https://doaj.org/article/0b6a4f1c3538405a88228d712db0338b

Zobrazit plný text záznamu

Akademický článek

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

Publikováno v: JCI Insight, Vol 7, Iss 24 (2022)

Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertai

Externí odkaz: https://doaj.org/article/8a5c7e6ab1d54951bb09cdce36a705c8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání